FDA defends heightened review requirement for flavored vapes at Fifth Circuit

The U.S. Food and Drug Administration defended a regulatory requirement before the Fifth Circuit Court of Appeals that vape manufacturers demonstrate flavored e-cigarettes provide greater smoking cessation benefits than tobacco-flavored alternatives.

The FDA's rule, issued under the authority of the Family Smoking Prevention and Tobacco Control Act, mandates that makers of candy and fruit-flavored vapes submit evidence showing these products outperform tobacco-flavored versions in converting smokers away from conventional cigarettes. The agency adopted this heightened review standard to balance two competing public health interests: reducing smoking rates versus limiting youth access to appealing flavored products.

Vape manufacturers challenged the requirement as arbitrary and unsupported by the statutory language, arguing the FDA lacks authority to impose comparative efficacy standards for nicotine delivery products. They contend the regulation imposes an impossible evidentiary burden, effectively banning flavored vapes without formal rulemaking procedures.

The FDA countered that Congress granted it discretionary authority to regulate tobacco products based on public health findings. Agency officials argued that flavored vapes pose documented risks to youth initiation while offering unproven benefits to adult smokers trying to quit. The comparative effectiveness standard, the FDA maintained, appropriately reflects the statutory requirement that manufacturers demonstrate products meet public health standards.

The Fifth Circuit's review examined whether the agency stayed within statutory bounds and followed proper administrative procedures. The outcome carries substantial commercial implications for the vape industry, worth billions annually. A ruling for manufacturers could enable broader marketing of flavored products. An FDA victory would likely narrow the market for non-tobacco flavored vapes absent specific cessation evidence.

The case reflects ongoing regulatory tension over how agencies balance competing health objectives when statutory language remains ambiguous. The decision will influence how the FDA applies comparative efficacy requirements to other tobacco products and nicotine delivery systems moving forward.